NYSE:BAXBaxter International Stock Price, Forecast & News

Baxter International's stock was trading at $77.97 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, BAX stock has increased by 8.6% and is now trading at $84.65. View which stocks have been most impacted by Coronavirus.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Baxter International in the last year. There are currently 5 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Baxter International.

Baxter International is scheduled to release its next quarterly earnings announcement on Thursday, July 30th 2020. View our earnings forecast for Baxter International.

Baxter International will be holding an earnings conference call on Thursday, July 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Baxter International Inc (NYSE:BAX) issued its quarterly earnings results on Thursday, April, 30th. The medical instruments supplier reported $0.82 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.73 by $0.09. The medical instruments supplier earned $2.80 billion during the quarter, compared to the consensus estimate of $2.74 billion. Baxter International had a net margin of 8.85% and a return on equity of 22.70%. The business's quarterly revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the company earned $0.76 earnings per share. View Baxter International's earnings history.

Baxter International declared a quarterly dividend on Tuesday, July 14th. Shareholders of record on Monday, August 31st will be given a dividend of $0.245 per share on Thursday, October 1st. This represents a $0.98 dividend on an annualized basis and a dividend yield of 1.16%. The ex-dividend date of this dividend is Friday, August 28th. View Baxter International's dividend history.

Baxter International declared that its Board of Directors has authorized a stock repurchase plan on Tuesday, November 13th 2018, which allows the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 6.1% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company's leadership believes its shares are undervalued.

20 brokerages have issued twelve-month price targets for Baxter International's shares. Their forecasts range from $84.00 to $105.00. On average, they anticipate Baxter International's share price to reach $96.60 in the next year. This suggests a possible upside of 14.1% from the stock's current price. View analysts' price targets for Baxter International.

Media headlines about BAX stock have trended extremely negative recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Baxter International earned a coverage optimism score of -4.3 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an effect on the stock's share price in the near term. View the latest news about Baxter International.

Baxter International saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 4,030,000 shares, an increase of 31.3% from the June 15th total of 3,070,000 shares. Based on an average daily volume of 3,100,000 shares, the short-interest ratio is presently 1.3 days. Currently, 0.8% of the shares of the company are short sold. View Baxter International's Current Options Chain.

Some companies that are related to Baxter International include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Stryker (SYK), Boston Scientific (BSX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Steris (STE), Insulet (PODD) and ABIOMED (ABMD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Baxter International investors own include CA (CA), Johnson & Johnson (JNJ), Honeywell International (HON), Cisco Systems (CSCO), AT&T (T), Pfizer (PFE), BlackRock (BLK), Verizon Communications (VZ), Abbott Laboratories (ABT) and Procter & Gamble (PG).

Baxter International trades on the New York Stock Exchange (NYSE) under the ticker symbol "BAX."

Baxter International's stock is owned by many different institutional and retail investors. Top institutional shareholders include Gateway Investment Advisers LLC (0.06%), State of Alaska Department of Revenue (0.03%), Fulton Breakefield Broenniman LLC (0.03%), Envestnet Asset Management Inc. (0.02%), Tsfg LLC (0.02%) and Dalton Greiner Hartman Maher & Co. (0.02%). Company insiders that own Baxter International stock include Albert P L Stroucken, Andrew Frye, Carole J Shapazian, Giuseppe Accogli, Jacqueline Kunzler, James R Gavin III, Jeanne K Mason, John D Forsyth, Peter S Hellman, Scott Pleau, Sean Martin, Third Point Llc and Thomas T Stallkamp. View institutional ownership trends for Baxter International.

BAX stock was sold by a variety of institutional investors in the last quarter, including Dalton Greiner Hartman Maher & Co., Envestnet Asset Management Inc., Gateway Investment Advisers LLC, State of Alaska Department of Revenue, IFM Investors Pty Ltd, First Citizens Bank & Trust Co., OLD Point Trust & Financial Services N A, and Private Trust Co. NA. Company insiders that have sold Baxter International company stock in the last year include Albert P L Stroucken, Andrew Frye, Giuseppe Accogli, Jacqueline Kunzler, James R Gavin III, Jeanne K Mason, and John D Forsyth. View insider buying and selling activity for Baxter International.

BAX stock was bought by a variety of institutional investors in the last quarter, including Fulton Breakefield Broenniman LLC, Exchange Traded Concepts LLC, Brasada Capital Management LP, Canandaigua National Corp, DNB Asset Management AS, Everence Capital Management Inc., Carlson Capital Management, and First United Bank Trust. View insider buying and selling activity for Baxter International.

Shares of BAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BAX stock can currently be purchased for approximately $84.65.

Baxter International has a market capitalization of $42.93 billion and generates $11.36 billion in revenue each year. The medical instruments supplier earns $1.00 billion in net income (profit) each year or $3.31 on an earnings per share basis. Baxter International employs 50,000 workers across the globe.

The official website for Baxter International is www.baxter.com.

Baxter International's mailing address is One Baxter Parkway DF2-1W, Deerfield IL, 60015. The medical instruments supplier can be reached via phone at 224-948-2000 or via email at [email protected]